News & analysis on the clinical development and manufacture of large molecule drugs
Novel nasal therapy hopes to reduce the amount of COVID-19 virus reaching the lungs
By Jane Byrne
- Last updated on
Another big hitter last month was a piece, first published in September, on a new preventative nasal spray treatment that could reportedly protect people from COVID-19 infection and prevent transmission.
The novel therapy was developed by Australian biotech company, Ena Respiratory, with a study indicating it significantly reduced COVID-19 virus levels in the nose and throat. It also reduced COVID-19 replication by up to 96%, found the research, which was performed by Public Health England (PHE) scientists.